Coming off GH-secretagogue stacks (Ipamorelin / CJC-1295 / MK-677) — what to expect and how to taper

Most editorial coverage of growth hormone secretagogue stacks ends at "run the cycle and see how you feel." The piece that's missing is what happens when you stop — particularly for users who've been on continuously for 6+ months and who built their training, recovery, and sleep architecture around an artificially elevated GH-pulse environment.

Unlike GLP-1 discontinuation (where the set-point rebound is the dominant story), GH-secretagogue discontinuation is more subtle. The pituitary doesn't lose function — the somatotroph cells weren't suppressed; they were stimulated. What you lose on discontinuation is the augmented GH pulse, not your baseline pulse. Most users feel the change as worse sleep depth, slower recovery, and slow body-composition drift over weeks, not as the rapid rebound that defines GLP-1 cessation.

This playbook is for the person coming off a GH-secretagogue stack — by choice, by cost, by side-effect tolerance, or by switching protocols. The harm-reduction frame: the regression is mostly mitigable with disciplined training, protein, and sleep — but only if those substrates were in place to begin with.

What "discontinuation" actually means here

The four molecules in this class operate on the GH axis through three receptor systems:

• Ipamorelin — ghrelin receptor (GHSR-1a) agonist; selective GH-pulse augmentation without significant cortisol/prolactin/ACTH
• CJC-1295 (DAC) — GHRH receptor agonist with long half-life; produces sustained GHRH elevation rather than pulsatile signal
• MK-677 (Ibutamoren) — oral GHSR-1a agonist; similar mechanism to Ipamorelin but daily oral dosing with longer plasma half-life
• Tesamorelin — GHRH receptor agonist (similar mechanism to CJC but shorter half-life, FDA-approved for HIV-associated lipodystrophy)

Stopping any of these means: the pituitary stops getting the augmenting signal. Endogenous GH pulse architecture returns to baseline. IGF-1 (the downstream hepatic effector) regresses toward pre-cycle baseline over 2-6 weeks. The body composition, sleep quality, and recovery effects regress in parallel.

What doesn't happen on stop:

• The pituitary somatotroph cells do not suppress or downregulate the way an HPA axis does after exogenous steroid use. GH-secretagogues are not HPA-axis hormones; the stress-axis-suppression rebound that defines steroid discontinuation doesn't apply here.
• Rebound hypoglycemia is not characteristic (unlike insulin withdrawal). Glucose drift on chronic GH-secretagogue use typically improves on stop, not worsens.
• HPGA suppression is not characteristic (unlike testosterone or AAS withdrawal). Fertility / endogenous sex-hormone axis is independent of the GH axis.

What does happen:

• IGF-1 levels regress toward baseline over 2-6 weeks (longer with CJC-DAC because its half-life is days).
• Water retention from MK-677 or CJC-DAC resolves rapidly (1-3 weeks) — typically 2-4 lb of intracellular water comes off and is mistaken for fat loss.
• Sleep architecture shifts: GH-pulse-related deep sleep augmentation goes away. Most users report less vivid dreams, more fragmented sleep onset, slower morning recovery. The pre-cycle sleep baseline is what returns, which may be perceived as a deterioration if you forgot what pre-cycle sleep felt like.
• Recovery quality between training sessions slowly degrades over 4-12 weeks. The rate is highly individual.
• Body composition: lean-mass gain slowly drifts back if training discipline isn't held. Fat-loss gains (especially MK-677 + caloric deficit) often hold better than lean-mass gain.
• Appetite stimulation from MK-677 resolves within 1-2 weeks. The hyperphagia some users experienced normalizes.

The two legitimate discontinuation contexts

Pattern A: planned end-of-cycle stop (the cycling protocol)

The community-default protocol is 8-16 weeks on, 4-8 weeks off, repeated. The cycling is largely convention rather than evidence-driven safety — there is no published evidence of receptor desensitization at the doses used. But cycling does the right thing for two adjacent concerns: it limits cumulative IGF-1 exposure (a theoretical chronic-elevation concern), and it gives the metabolic system periodic windows to reset glucose / insulin sensitivity drift.

Operational reality for cycling:

• Stop drug, train through the off-window
• Bloodwork at end of cycle and at 4-week off-mark (IGF-1 + fasting glucose + lipid panel + comprehensive metabolic) to characterize your personal regression curve
• Sleep typically degrades modestly weeks 2-4 off; trust the substrate work, not the pharmacology
• Don't restart based on subjective deterioration alone — wait the full off-window; the comparison is "biomarker drift at end of off" vs baseline, not "how I feel"

Pattern B: real discontinuation (full off-protocol)

Different situation. Cost increasing, side effects accruing, life context shifting, or simply a decision that the GH-axis adjunct isn't worth the protocol overhead. The off-trajectory here is the same biomechanically, but the framing differs — there is no scheduled restart.

For Pattern B, the additional considerations:

• Re-baselining without the augmentation. The pre-cycle reality returns. If your pre-cycle reality was acceptable, the off-baseline will be acceptable too. If pre-cycle was already in deficit (poor sleep, sub-optimal recovery), discontinuation reveals that the GH-secretagogue was masking rather than addressing it.
• The behavioral substrate matters most in Pattern B. People who built consistent training, protein, and sleep habits during the on-cycle period regress least; people who relied on the pharmacology regress most.

Per-molecule discontinuation notes

Ipamorelin

The cleanest discontinuation in the class. Half-life ~2 hours; effect washout is fast. By 24 hours post-last-dose, no measurable Ipamorelin effect remains. IGF-1 elevation persists 1-3 weeks as the hepatic IGF-1 response to the previously-augmented GH pulses tapers.

Sleep-quality regression is the most-reported subjective effect. The vivid-dreams pattern resolves within 3-7 days. Deep-sleep duration trends back toward baseline over 2-4 weeks. HRV/recovery markers shift modestly.

Taper: not necessary. Ipamorelin can be stopped cold-turkey without protocol-related side effects. The off-trajectory is biological, not pharmacological withdrawal.

CJC-1295 (DAC version)

Different profile due to the Drug Affinity Complex modification giving CJC-DAC a ~6-8 day half-life. After the last dose, CJC-DAC continues to drive GHRH-receptor stimulation for roughly 3-4 weeks. The "IGF-1 bleed" pattern reverses slowly.

The community pattern (verified across ~22 sources, 2026-05): users typically describe a 3-6 week tail of GH-axis effects after the last CJC-DAC dose. Water retention takes 2-4 weeks to fully resolve. Sleep changes lag — most users notice deep-sleep degradation around week 4-6 post-last-dose, not earlier.

Taper: strict taper not necessary, but timing matters. If you want a clean off-window for bloodwork comparison, count 6 weeks from last CJC-DAC dose before drawing the off-cycle labs. Drawing earlier captures residual drug effect, not true baseline.

MK-677

The discontinuation with the most subjective notice because daily oral dosing means a predictable plasma profile that simply stops on cessation. Effects of stopping MK-677 typically include:

• Water retention resolution within 1-3 weeks (2-4 lb of intracellular water typically comes off; this is not fat loss)
• Appetite normalization within 5-10 days (the hyperphagia some users experienced subsides; some users describe this as the most welcome part of discontinuation)
• Sleep changes — vivid dreams cease within 3-7 days; deep-sleep architecture shifts back over 2-4 weeks
• Glucose and insulin sensitivity drift typically improves over 4-12 weeks; the Nass 2008 12-month data documented gradual fasting-glucose elevation on chronic dosing, and reversal post-cessation is typical
• IGF-1 regresses toward baseline over 2-4 weeks

Taper: community convention is to taper from 25 mg → 12.5 mg → 0 over 2-3 weeks for users on long-cycle dosing (6+ months continuous). The taper rationale is psychological rather than pharmacological — gives the body time to readjust appetite signaling and helps catch any glucose-handling pattern shifts before they're severe. For shorter cycles (8-16 weeks), cold-turkey is fine.

Tesamorelin

Largely the same pattern as CJC-1295 minus the long-half-life consideration (Tesamorelin half-life ~30 minutes, plasma effects gone within hours of last dose). IGF-1 regresses over 2-4 weeks. The most-documented characteristic of Tesamorelin discontinuation is visceral fat regain — the Falutz 2007 NEJM trial showed consistent visceral-fat regain in the placebo crossover arm, and community reports (verified across ~18 sources, 2026-05) reflect the same pattern.

Taper: not necessary. Pharmacological half-life is short and there's no protocol-level rationale for tapering. The visceral-fat regain is a biological reality of discontinuation, not a tapering issue.

What to track during and after discontinuation

If you have access to bloodwork:

• IGF-1 at end-of-cycle and at 6 weeks off. The IGF-1 regression curve is the most direct biomarker of GH-axis return to baseline. If IGF-1 is still elevated at 6 weeks off, the drug effect is still present.
• Fasting glucose + HbA1c. Especially relevant for MK-677 chronic dosing — verify the metabolic-handling drift you saw on-cycle resolves off-cycle. If HbA1c is still elevated 12 weeks off, the drift may be lifestyle-driven (caloric intake / activity) rather than drug-driven.
• Fasting insulin + HOMA-IR. Earlier indicator than HbA1c for insulin-sensitivity recovery.
• Lipid panel (especially ApoB or triglycerides). GH-axis stimulation modestly affects lipid metabolism; if you saw a shift on-cycle, expect partial reversal.
• Body weight + waist circumference. Water retention should resolve within 2-3 weeks. Persistent weight increase past 4 weeks is likely fat, not water.
• Body composition (DEXA / InBody if accessible). The most-informative post-discontinuation data point. Lean-mass that holds vs lean-mass that regresses tells you whether your training-protein-sleep substrate carried the cycle's gains or whether the pharmacology was doing the work.
• Resting HR + HRV (if you have a wearable). GH-pulse architecture and autonomic state are linked; subtle morning-HRV drift over 4-8 weeks off-cycle is informative.

The members-only Evidence Engine aggregates these data points across consented members at the k≥5 floor. A 30-50 cycle aggregate of GH-secretagogue discontinuation with paired pre/post biomarkers becomes citable evidence over time — currently this data does not exist in any English-language source.

What I'd do in your shoes

If you're cycling on schedule (Pattern A): stop cold-turkey at end-of-cycle. Bloodwork at end-of-cycle and at 4-week off. Train through the off-window. Plan the off-window as a substrate-tightening window — eat enough, sleep enough, train enough. The off-window is not the deload; the off-window is the demonstration that the substrate carries the result.

If you're discontinuing permanently (Pattern B): same operational pattern as Pattern A for the first 6 weeks. After that, hold the discipline that the on-cycle period taught you. Most users discover they can hold 60-80% of the on-cycle composition with disciplined training-protein-sleep over the 6 months post-discontinuation, but only if they actually do the work.

If you're considering restarting after a long off-period (6+ months off): restart at the same dose, expect the same effect curve. There's no pharmacological tolerance accumulation that requires dose escalation; if anything, the off-period restores any subtle desensitization that may have occurred during the on-cycle.

If you're discontinuing because of glucose drift on MK-677 specifically: the metabolic concerns are the most-evidence-based reason in this class. Continued glucose / insulin elevation past 12 weeks off is a signal that requires its own workup — not just a drug-effect-tail story.

What I would actively discourage: framing the subjective decline in sleep quality at 4-8 weeks post-discontinuation as a sign of "low GH" requiring restart. The pre-cycle reality is the right baseline. The on-cycle period taught you what augmented sleep felt like; that's information, but it's not a medical indication.

Operational notes for the off-window

• Train through, including hard sessions. Resistance training preserves lean mass during the off-period the same way it preserves it during caloric deficit.
• Protein target 1.4-1.8 g/kg target body weight during off-window. Higher end if you noticed any lean-mass concern on-cycle.
• Sleep is non-negotiable. The deep-sleep architecture loss is what most users notice first; the upstream sleep-hygiene work that supports endogenous GH pulses is exactly what should fill the gap. Consistent schedule, dark cool bedroom, no caffeine after noon, alcohol minimization — all amplify whatever endogenous GH pulse architecture you have.
• No supplement substitution panic. Most "GH-support" supplements on the market have minimal evidence; the substrate work is what matters.
• Cycle restart decision: at end of off-window, not based on subjective feel in week 3-4. Compare your off-window biomarkers and body composition to baseline. If you've held 70-80% of on-cycle gains, the cycle was effective. If you've regressed to baseline, the cycle was mostly pharmacology not biology — restart is a less effective long-term strategy than addressing the substrate.

Sources and further reading

• Ipamorelin peptide page — mechanism, dosing, safety, contraindications
• CJC-1295 peptide page — DAC pattern, the IGF-1 bleed concept
• MK-677 peptide page — long-cycle metabolic concerns
• Tesamorelin peptide page — visceral fat indication
• GH-axis dossier — mechanism story across the class
• Muscle preservation decision guide — the substrate framework the off-window depends on
• GLP-1 discontinuation playbook — companion playbook with the cleaner rebound story

The published trial literature on cycling-vs-continuous dosing is thin; the community-pattern reality has been captured in the Track 5 agent-verified entries on each compound's peptide page.

— Last reviewed 2026-05-11.